Travere Therapeutics

Travere Therapeutics ( (TVTX) ) has issued an announcement. , will step down from his roles, including his board seat, effective December 1, 2026, under a detailed Transition and Separation Agreement. Dube will remain as an employee during a transition period and then serve as executive advisor and consultant through up to mid-2028, with continued salary, 2026 bonus eligibility, COBRA coverage and specified treatment of his equity awards, including potential acceleration in certain termination or change-in-control scenarios. Bradley L. Campbell, a veteran biopharmaceutical executive and former CEO of Amicus Therapeutics, has been appointed to succeed Dube as Travere’s President, Chief Executive Officer and director effective December 1, 2026.

5 million in options and time-based RSUs, a performance-based RSU grant in early 2027 and comprehensive severance and accelerated vesting protections, including enhanced benefits in the event of termination in connection with a change in control. 00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page . Spark’s Take on TVTX Stock According to Spark, TipRanks’ AI Analyst, TVTX is a Neutral. The score is driven primarily by improving operating fundamentals and cash generation, but is held back by significant balance-sheet leverage risk (very high debt vs.

thin equity). The earnings call was a positive catalyst due to strong FILSPARI growth and reiterated outlook, while technicals are moderately constructive. Valuation remains a headwind given ongoing losses (negative P/E) and no dividend yield support. To see Spark’s full report on TVTX stock, click here . More about Travere Therapeutics Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, operating in a market that values experienced leadership in drug development, commercialization and regulatory strategy.

The company’s positioning in the specialty and orphan drug space makes executive experience in biopharma operations and market access particularly material for investors and other stakeholders.